A Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta

Title:A Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta

Volume: 31

Author(s): Huayu Zhang, Qian Xu, Yimeng Zhao, Naiqi He, Zhong Ren, Qiong Xiang, Zhihan Tang*Lushan Liu*

Affiliation:

• Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan Province 421001, P.R. China

• Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan Province 421001, P.R. China

Keywords: Proprotein convertase subtilisin/kexin type 9, alzheimer’s disease, amyloid beta, blood-brain barrier, neuroinflammation, neuronal cell death.

Abstract: The proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to a member of the proprotein convertase (PC) family, which is mainly secreted by the liver and plays a central role in lipid metabolism. Furthermore, PCSK9 plays a multifunctional role in promoting the inflammatory response, inducing cell apoptosis and pyroptosis and affecting tumor homeostasis. The brain is the organ with the richest lipid content. Incidentally, PCSK9 increased in many brain diseases, including brain injury and Alzheimer’s disease (AD). Consequently, the relationship between PCSK9 and brain diseases has attracted increasing research interest. Amyloid beta (Aβ) accumulation is the central and initial event in the pathogenesis of AD. This study focuses on the effects of PCSK9 on Aβ accumulation in the brain via multiple modalities to explore the potential role of PCSK9 in AD, which is characterized by progressive loss of brain cells by increasing Aβ accumulation. The study also explores the new mechanism by which PCSK9 is involved in the pathogenesis of AD, providing interesting and innovative guidance for the future of PCSK9-targeted therapy for AD.

Cite this article as:

Zhang Huayu, Xu Qian, Zhao Yimeng, He Naiqi, Ren Zhong, Xiang Qiong, Tang Zhihan*, Liu Lushan*, A Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta, Current Medicinal Chemistry 2024; 31 () . https://dx.doi.org/10.2174/0109298673269288231123095215